Patient characteristics at baseline grouped according to MRD stratification at maximal response
| Characteristic . | MRD+ . | MRD− . | P . |
|---|---|---|---|
| Male/female, n (%) | 35 (52.2)/32 (47.8) | 38 (52.8)/34 (47.2) | .949 |
| Mean age (SD), y | 61.4 (8.5) | 57.8 (10.2) | .029 |
| Serum creatinine ≥2 mg/dL, n (%) | 8 (11.9) | 17 (23.6) | .073 |
| HR cytogenetics, n (%) | 15 (41.7) | 14 (32.6) | .403 |
| ISS I/II/III, n (%) | 22 (35.5)/22 (35.5)/18 (29) | 21 (31.3)/17 (25.4)/29 (43.3) | .215 |
| Positive PET-CT, n (%) | 5 (8.8) | 10 (15.4) | .262 |
| Characteristic . | MRD+ . | MRD− . | P . |
|---|---|---|---|
| Male/female, n (%) | 35 (52.2)/32 (47.8) | 38 (52.8)/34 (47.2) | .949 |
| Mean age (SD), y | 61.4 (8.5) | 57.8 (10.2) | .029 |
| Serum creatinine ≥2 mg/dL, n (%) | 8 (11.9) | 17 (23.6) | .073 |
| HR cytogenetics, n (%) | 15 (41.7) | 14 (32.6) | .403 |
| ISS I/II/III, n (%) | 22 (35.5)/22 (35.5)/18 (29) | 21 (31.3)/17 (25.4)/29 (43.3) | .215 |
| Positive PET-CT, n (%) | 5 (8.8) | 10 (15.4) | .262 |